louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03557866: Kinematic Parameters of Running in Individuals With Pronated Foot
Official title: Kinematic Parameters of Running in Individuals With Pronated Foot
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pronation; Ankle
Keywords: foot posture
running
foot index
Lead sponsor: University of Haifa
Sponsor class: OTHER
First posted: 2018-06-15
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: two groups. Individuals with and without pronated foot.
Primary purpose: SCREENING

Brief summary: The aim of the study is to examine the kinematic parameters of individuals with pronated foot compared with individuals with normal foot

Detailed description: Individual with and without pronated foot will be recruited. Pronation will be defined according to navicular drop test. Inclusion criteria : individual who run on a regular basis at least 3 times per week for one hour, can run 5 Km in less then 40 minutes, without past injuries during the last year of Achilles tendon or other lower extremities pain.

Individuals will be asked to run for 5 Km in self selected velocity. The Milestone pod device will be used to monitor kinematic parameters.

functional test will be conducted before and after the running as follows: heel raise test and one leg hop for distance test.

Eligibility criteria: Inclusion Criteria:

* running on a daily basis at least 3 times per week with minimum of 1 hour
* capable to run 5 km in less then 40 minutes
* willing to participate in the study

Exclusion Criteria:

* previous surgery in lower extremities
* Achilles tendon pain during the last year

Primary outcomes:
measure: stride length
timeFrame: up to 6 months
measure: cadence
timeFrame: up to 6 months
Secondary outcomes:
measure: velocity
timeFrame: up to 6 months
measure: heel raise test
timeFrame: up to 6 months
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: University of Haifa
Study officials:
affiliation: University of Haifa
name: Gali Dar, PHd
role: PRINCIPAL_INVESTIGATOR
References:
citation: McPoil TG, Cornwall MW, Medoff L, Vicenzino B, Fosberg KK, Hilz D. Arch height change during sit-to-stand: an alternative for the navicular drop test. J Foot Ankle Res. 2009 May 18;2:17. doi: 10.1186/1757-1146-2-17.
citation: Murley GS, Menz HB, Landorf KB. Foot posture influences the electromyographic activity of selected lower limb muscles during gait. J Foot Ankle Res. 2009 Nov 26;2:35. doi: 10.1186/1757-1146-2-35.
Clinical trial NCT06731166: Effectiveness of Video Monitoring and Care Transition for Heart Failure Patients (EVIT-HF): Randomized Clinical Trial
Official title: Effectiveness of Video Monitoring and Care Transition for Heart Failure Patients (EVIT-HF): Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF)
Keywords: Heart Failure
Nursing Care
Clinical Trial
Telenursing
Lead sponsor: Federal University of Uberlandia
Sponsor class: OTHER
Collaborators: name: Federal University of Rio Grande do Sul
name: Universidade Federal do Triangulo Mineiro
First posted: 2024-12-12
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this clinical trial is to measure the effectiveness of video monitoring associated with the transition of care for patients with heart failure.

The main questions it aims to answer is: Is video monitoring superior to monitoring via audio calls in patients with heart failure?

Researchers will compare monitoring by video to a monitoring by audio to see if drug videomonitoring works to improve selfcare in heart failure and other outocomes.

Participants will:

intervention group receive video calls guided by cardiologist nurses at 7, 30, 60, 180 and 365 days after hospital discharge.

the control group will receive audio calls for data collection, at the same time mentioned.


Eligibility criteria: Inclusion Criteria:

* Patients aged 18 years or older;
* Admitted for decompensated HFrEF
* Ejection fraction less than 40% confirmed by echocardiogram performed in the last 3 months
* Who access to a mobile device with internet access

Exclusion Criteria:

* heart transplant waiting list;
* who had undergone coronary artery bypass in the last 3 months ;
* who were in palliative care;
* who had a life expectancy of less than 1 year

Primary outcomes:
measure: Self-Care Behaviors Assessed by the European Self-Care Scale in Patients with Heart Failure
timeFrame: 365 days after discharge
Secondary outcomes:
measure: Rate of Cardiovascular Mortality within 365 Days Post-Discharge
timeFrame: 365 days after discharge
Other outcomes:
measure: Hospitalization Rates for Heart Failure within 365 Days Post-Discharge
timeFrame: 365 days after discharge
measure: Heart Failure Knowledge Assessed by the HF Knowledge Questionnaire
timeFrame: 365 days after discharge
measure: Adherence to Heart Failure Treatment Regimens asseded by "Adherence to HF treatment instrument"
timeFrame: 365 days after discharge
measure: Quality of Life Assessed by the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
timeFrame: 365 days after discharge
measure: Cardiorespiratory Fitness Assessed by the Veterans Specific Activity Questionnaire (VSAQ)
timeFrame: 365 days after discharge
Locations:
Study officials:
affiliation: Federal University of Uberlandia
name: OMAR DE ALMEIDA NETO, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00510666: Comparison of Butorphanol and Tramadol Associated Patient-Controlled Analgesia (PCA) After Hysterectomy
Official title: Butorphanol and Tramadol for Morphine PCA Pain Management After Total Hysterectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Postoperative Pain
Hysterectomy
Keywords: Pain, Postoperative
Analgesics, Opioid
Analgesia, Patient-Controlled
Pain Measurement
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
Collaborators: name: HRSA/Maternal and Child Health Bureau
First posted: 2007-08-02
Enrollment: 841
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Intravenous patient-controlled analgesia (PCA) is a popular technique for postoperative pain management. Although several drugs are recognized as effective therapeutic options, optimal selection of drugs in hysterectomy patients underwent different anesthesia treatments remains unknown explicitly. The investigators hypothesized that butorphanol and tramadol can produce different analgesic effects with intravenous PCA after abdominal hysterectomy.


Eligibility criteria: Inclusion Criteria:

* ASA physical status I-II
* Chinese
* 19-64yr
* Uterus myoma

Exclusion Criteria:

* Allergy to opioids, a history of the use of centrally-acting drugs of any sort, chronic pain and psychiatric diseases records.
* Participants younger than 18yr，older than 65yr or pregnancy was eliminated.
* Due to the significant changes in vital signs might affect cognition of pain and that of sensation, over 20% variation of these records from the baselines or below 92% of SpO2 under 20-40% nasal tube oxygen at any time should be excluded from the study.
* Those who were not willing to or could not finish the whole study at any time.
* Any patient who exhibited a combative or incoherent state of PCA analgesia would be excluded from the study.
* Allergy to local anesthetics.
* Failed to perform the epidural catheterization.
* Those who demonstrated significant nerve-associated side effects from the insertion of the epidural needle.

Primary outcomes:
measure: VAS pain scoring;
timeFrame: 5 months
Secondary outcomes:
measure: VAS sedation scoring; VAS happiness scoring; Adverse effects; Patient's overall conditions.
timeFrame: 5 months
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Nanjing Maternal and Child Care Hospital
state: Jiangsu
Study officials:
affiliation: Nanjing Medical University
name: XiaoFeng Shen, MD
role: STUDY_CHAIR
References:
citation: Wang F, Shen X, Liu Y, Xu S, Guo X. Continuous infusion of butorphanol combined with intravenous morphine patient-controlled analgesia after total abdominal hysterectomy: a randomized, double-blind controlled trial. Eur J Anaesthesiol. 2009 Jan;26(1):28-34. doi: 10.1097/EJA.0b013e32831a6aa2.
Clinical trial NCT01074866: Neurally Adjusted Ventilatory Assist for Non Invasive Ventilation and Patient-ventilator Interaction
Official title: The Effects of Neurally Adjusted Ventilatory Assist (NAVA) on Improving Patient-ventilator Interaction in Patients Undergoing Ventilation for Acute Respiratory Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Non Invasive Ventilation
Patient Ventilator Interaction
Keywords: Mechanical ventilation
Non invasive Ventilation
Patient-ventilator interaction
Pressure support
Neurally adjusted ventilatory assist
Lead sponsor: University Hospital, Geneva
Sponsor class: OTHER
Collaborators: name: University Hospital St Luc, Brussels
name: University Hospital Sart Tilman, Liege
name: University of Lausanne Hospitals
name: Notre Dame de Grace Hospital, Gosselies
First posted: 2010-02-24
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The present study aims to compare various parameters reflecting patient-ventilator synchrony during standard pressure support (PS) and Neurally Adjusted Ventilatory assist (NAVA) in a group of patients receiving non invasive ventilation (NIV)for an episode of acute respiratory failure of various origin.

Detailed description: The present study aims to compare various parameters reflecting patient-ventilator synchrony during standard pressure support (PS) and Neurally Adjusted Ventilatory assist (NAVA) in a group of patients receiving non invasive ventilation (NIV)for an episode of acute respiratory failure of various origin. The subgroup of COPD patients will be analyzed separately. The effects of various setting of Neurally adjusted ventilatory assist on patient-ventilator interaction will also be explored.

Eligibility criteria: Inclusion Criteria:

* Patients admitted to the ICU and treated with Non invasive ventilation for acute respiratory failure of any origin

Exclusion Criteria:

* severe hypoxemia requiring an FIO2\>0.6
* hemodynamic instability
* known oesophageal problem
* active upper gastro-intestinal bleeding
* any other contraindication to the insertion of a naso-gastric tube
* impaired consciousness or absence of patient cooperation
* facial or laryngeal lesions contraindicating the use of NIV
* poor short term prognosis

Primary outcomes:
measure: Patient-ventilator synchronization parameters
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: St Luc University hospital
city: Liege
country: Belgium
facility: Bernard Lambermont
city: Geneva
country: Switzerland
facility: HUG, University Hospital
city: Lausanne
country: Switzerland
facility: CHUV University hospital of Lausanne
Study officials:
affiliation: HUG, University hospital Geneva
name: Didier Tassaux, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03000166: Step-Up Intervention for Self-Management of Fatigue in Young Adults Receiving Chemotherapy
Official title: Step-Up Intervention for Self-Management of Fatigue in Young Adults Receiving Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Young Adult, Cancer, Physical Activity
Lead sponsor: University of Wisconsin, Milwaukee
Sponsor class: OTHER
Collaborators: name: Froedtert Hospital
name: Children's Hospital and Health System Foundation, Wisconsin
name: Medical College of Wisconsin
First posted: 2016-12-21
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of the study is to determine the impact of a physical activity intervention on the self-management of fatigue in young adults receiving chemotherapy. Half of the participants will receive an intervention which includes education and resources to set physical activity goals and monitor progress toward goals.

Detailed description: Interventions to increase physical activity have been shown to relieve fatigue in patients receiving chemotherapy, but no studies have tested a physical activity intervention to improve fatigue in young adults receiving chemotherapy. This study will determine the impact of a physical activity intervention on the self-management process variables of self-efficacy and self-regulation and their relationships to physical activity and fatigue severity in young adults receiving chemotherapy.

Eligibility criteria: Inclusion Criteria:

* have a diagnosis of cancer;
* are within the first two months of a chemotherapy regimen that will last at least another 3 months;
* are ambulatory without assistance;
* have written consent from their physician to participate;
* have the ability to understand English;
* have access to a computer and the Internet.

Exclusion Criteria:

* symptoms of uncontrolled cardiopulmonary disease, neurological disease
* delayed wound healing
* high risk of bone fracture
* pre-existing peripheral neuropathy

Primary outcomes:
measure: Self-efficacy for Physical Activity
timeFrame: Completion of post-study measures (average 15 weeks)
measure: Self-regulation of Physical Activity
timeFrame: Completion of post-study measures (average 15 weeks)
Secondary outcomes:
measure: Steps Per Day
timeFrame: Completion of post-study measures (average 15 weeks)
measure: Fatigue Severity
timeFrame: Completion of end-of-study measures (average 15 weeks)
Other outcomes:
Locations:
city: Milwaukee
country: United States
facility: Froedtert Hospital
state: Wisconsin
city: Milwaukee
country: United States
facility: Children's Hospital of Wisconsin
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Milwaukee
name: Rachel Schiffman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03252366: Maxillary Sinus Elevation and Simultaneous Implant Placement
Official title: MAXILLARY SINUS ELEVATION USING GELFOAM (ABSORBABLE GELATIN) VERSUS XENOGRAFT (TUTOGEN) and SIMULTANEOUS IMPLANT PLACEMENT:Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Maxillary Sinus
Keywords: MAXILLARY SINUS ELEVATION ,Simultaneous implant placement
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-08-17
Enrollment: 18
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: using gel foam \[ absorbable gelatin \] in maxillary sinus elevation which act as a space maintainer and alternative to bone filler for new bone formation in the maxillary sinus and its advantages for patients undergoing maxillary sinus elevation with simultaneous implant placement as regards the implant stability and amount of bone height gain compared to conventional maxillary sinus elevation by xenograft.

Detailed description: One of the main problem for posterior maxilla it becomes atrophic after extraction of the teeth and this followed by Pneumatization of the maxillary sinus, the atrophy of the alveolar process is a common reason for the limited availability of alveolar bone for implant placement in the posterior maxilla.

Numerous techniques designed to increase bone volume in the maxillary sinus region have been proposed. They were mostly based on the insertion of various materials into a void created between the sinus (Schneiderian) membrane and the bony walls of the maxillary sinus. (Sohn et al 2008) reported simultaneous placement of implants, and insertion of gelatin sponges demonstrate new bone formation through clinical and radiographic evaluations. New bone formation was verified by stabilization of the elevated sinus membrane from the tenting effect of placement of dental implants and absorbable gelatin sponge without any bone graft material. This study shows that there is great potential for new bone formation in the maxillary sinus without the use of additional bone grafts. Systemic review showed that the survival rate for implants utilizing xenografts was statistically the same as for implants placed in particulate autogenous bone grafts .

Eligibility criteria: Inclusion Criteria:• Patients with atrophic maxilla and pneumatization of the maxillary sinus with residual bone height from 3 to 5mm .

* Both sexes.
* No intraoral soft and hard tissue pathology.
* No systemic condition that contraindicate implant placement.

Exclusion Criteria:• Sinus pathology.

* Heavy smokers more than 20 cigarettes per day .
* Patients with systemic disease that may affect normal healing.
* Psychiatric problems.
* Disorders to implant are related to history of radiation therapy to the head and neck neoplasia, or bone augmentation to implant site.

Primary outcomes:
measure: Amount of bone gained:
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05056766: How Does the Clinical and Paraclinical Efficacy of an Oral Appliance Evolved According to Propulsion: Control With Each mm of Advancement
Official title: How Does the Clinical and Paraclinical Efficacy of an Oral Appliance Evolve According to Propulsion: Control With Each mm of Advancement"
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiratory Tract Diseases
Keywords: oral appliance
Lead sponsor: Centre Hospitalier de Valence
Sponsor class: OTHER
Collaborators: name: ResMed
First posted: 2021-09-27
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: adult patients, with primary Moderate sleep apnea or Severe sleep apnea with failure continuous positive airway pressure( CPAP).

Brief summary: The OAMMM study is a mono-centrer , non interventional, prospective study, carried out in CH Valence

Oral Appliance is indicated for first line moderate sleep Apnea Syndrome or severe sleep Apnea Syndrome after failure of positive airway pressure (CPAP).

Clinical impact of each mm advancement of Oral Appliance is imperfectly assessed.

The study aim to assess clinical and paraclinical efficacy of an oral Appliance on each mm of advancement.

Detailed description: Oral appliance will be delivered with a propulsion at 50% of the maximum advance and the investigator will titrate the advance according to the usual method

Polygraphy and clinical effectiveness of the Oral appliance will be evaluate

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years old
* Moderate sleep apnea diagnosis with clinical signs
* Severe sleep apnea with failure continuous positive airway pressure( CPAP)

Exclusion Criteria:

* previous sleep apnea treatment for Moderate sleep apnea
* refusal to participate in research
* Patient under guardianship, deprived of liberty, safeguard of justice

Primary outcomes:
measure: apnea-hypopnea index
timeFrame: 6 months
Secondary outcomes:
measure: Epworth Sleepiness Scale score
timeFrame: 6 months
measure: pichot fatigue questionnaire
timeFrame: 6 months
Other outcomes:
Locations:
city: Valence
country: France
facility: CH Valence
Study officials:
affiliation: CH VALENCE
name: Guillaume BUIRET, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01455766: Volumetric Monitoring in Major Lung Surgery
Official title: Pulmonary Edema Following Major Thoracic Resections: a Value of Perioperative Volumetric Monitoring
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pneumonectomy
Acute Pulmonary Edema
Keywords: postpneumonectomy pulmonary edema
extravascular lung water
Lead sponsor: Northern State Medical University
Sponsor class: OTHER
Collaborators: name: Regional hospital of Arkhangelsk
name: University of Tromso
First posted: 2011-10-20
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population includes the patients scheduled for extended thoracic resections (lobar resection and pneumonectomy) due to bronchial cancer or severe destructive pulmonary infection (abscess and/or pneumonia).

Brief summary: The hypothesis of this observational single-center clinical study was to explore the volumetric hemodynamic monitoring in the perioperative period in major and risky thoracic intervention. The investigators monitored the changes in the volumes of blood in the central vessels and heart chambers as well as a volume of fluid in pulmonary tissue (i. e. extravascular lung water).

Detailed description: The goal of this observational study is to investigate into changes in volumetric hemodynamic parameters obtained with a technique of transpulmonary indicator dilution after major thoracic intervention, including pneumonectomy and lobar resections. The important parameters of hemodynamics were monitored throughout the intervention and 48 hrs postoperatively, including extravascular lung water index, global end-diastolic volume index, etc.

Eligibility criteria: Inclusion Criteria:

* Informed consent
* Age above 18 and below 80
* Confirmed malignant bronchial neoplasm or
* Destructive pulmonary infection

Exclusion Criteria:

* Pregnant
* Severe pulmonary hypertension
* Pulmonary tuberculosis
* Severe occlusive atherosclerosis of lower extremities

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Arkhangelsk
country: Russian Federation
facility: Regional Hospital of Arkhangelsk
state: Arkhangelsk Region
Study officials:
affiliation: Northern State Medical University
name: Vsevolod V. Kuzkov, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Regional hospital of Arkhangelsk
name: Mikhail M. Orlov, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Northern State Medical University
name: Mikhail Y. Kirov, MD, PhD
role: STUDY_CHAIR
affiliation: University of Trmsoe, Tromsoe, Norway
name: Lars J. Bjertnaes, MD, PhD
role: STUDY_DIRECTOR
References: